Printer Friendly

PolyPid Announces First Patient Enrolled in Confirmatory Clinical Trial, Evaluating Performance and Safety of BonyPid-1000(TM), an Antibiotic Eluting Bone Void Filler.

PETAH TIKVA, Israel, December 2, 2015 /PRNewswire/ --

PolyPid Ltd., an emerging clinical stage specialty pharmaceutical company, focused primarily on the development of post-surgical anti-infection pipeline, announced today the enrollment of the first patient in the confirmatory clinical trial of BonyPid-1000(TM), a doxycycline loaded synthetic bone substitute.

The BonyPid-1000-103 trial is a randomized, single-blind standard of care controlled study and is expected to be conducted on a total of 64 patients with severe open tibia fractures (Gustilo IIIA and IIIB), at five sites in Israel and three in Asia. The primary endpoint of the study is to determine performance and safety of BonyPid-1000(TM) on bone healing in traumatic open fracture patients, over a period of six and 12 months, compared with standard of care. The first patient has been enrolled at the Tel Aviv Sourasky Medical Center, Israel.

Dr. Noam Emanuel, PolyPid's CTO, stated "We are very pleased to commence our final, CE mark certification clinical trial for BonyPid-1000(TM), our PLEX based product addressing such a significant unmet medical need. This study expands our existing successful clinical data". Dr. Emanuel added "Severe open fracture patients are highly prone to infection at the fracture site causing an increased number of surgical interventions, longer healing time and higher amputation rates."

About BonyPid-1000

BonyPid-1000(TM) is a bone graft substitute containing a broad-spectrum antibiotic, doxycycline hyclate, to reduce microbial colonization on the bone void filler. The antibiotic is released locally over a prolonged period of four weeks. BonyPid-1000(TM) has completed sucssesfully pilot clinical trials in open fracture indication, demonstrating excellent safety and efficacy results, including 0% infections in the target fracture and 0% amputations after 6-12 months follow up (vs. an average of 25% and 7% respectively in a historical control group of patients).

About PolyPid

PolyPid is a clinical stage, emerging specialty pharmaceutical company, developing, manufacturing and commercializing products based on a proprietary platform named PLEX(TM) (Polymer-Lipid Encapsulation matriX), in the field of extended release, local drug delivery. PLEX(TM)-based protected drug reservoirs enable prolonged delivery of drugs, including biologics, over periods ranging from days to several months. The application of PLEX(TM) technology enables optimized drug treatment regimens by predetermining release rates and durations, a rare combination of attributes.

PolyPid's lead product, D-PLEX(TM), is a secured antibiotic drug reservoir. It provides safe and effective local anti-bacterial preventive measure and eradication at the target site by administration during surgical procedures. After surgery the reservoir constantly releases the entrapped antibiotic over several weeks. It thus allows for prolonged infection prevention or treatment and also has the potential to eradicate resistant bacteria. For additional company information, visit

Company contact: Dikla Czaczkes Akselbrad Chief Strategy Officer +972-74-7195753 or: David Kanaan Kanaan Public Relations Tel.: +972-54-4255307 e-mail:

SOURCE PolyPid Ltd.

COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:7ISRA
Date:Dec 2, 2015
Previous Article:Automatic Number Plate Recognition System Market Worth 1.05 Billion USD by 2020.
Next Article:PowerSecure Expands Energy Efficiency Capabilities With Acquisition Of ESCO Energy Services Company.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters